For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Transkaryotic Therapies, Inc.

USPTO Granted Patents = 40

Trademarks = 2

Forward Citations = 1,233

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Douglas A Treco (31 out of 61 patents)

Richard F Selden (28 out of 30 patents)

Michael W Heartlein (26 out of 175 patents)

4. Carol M Kinoshita (5 out of 6 patents)

5. Marianne Borowski (5 out of 11 patents)

6. Melanie D Williams (5 out of 5 patents)

7. Michael F Concino (4 out of 27 patents)

8. Frances P Gillispie (4 out of 4 patents)

9. Jeffrey F Lemontt (4 out of 7 patents)

10. Rochelle Mineau-Hanschke (4 out of 4 patents)

11. Allan M Miller (4 out of 4 patents)

12. Peter Francis Daniel (1 out of 5 patents)

13. Evguenii Ivanov (1 out of 1 patent)

14. Thomas J Schuetz (1 out of 1 patent)

15. Brian M Hauge (1 out of 1 patent)

Core Competencies:

Chimeric Polypeptides

Messenger RNA

Gene Therapy

Protein Delivery

Erythropoietin

Insulinotropin

Homologous Recombination

Hybrid Matrix Implants

Targeted DNA Introduction

Genomic Sequences

Clonal Cell Strains

Transfected Human Cells

40 patents: Sort by Forward Citations

1. 7122354 - Nucleic acid encoding a chimeric polypeptide (2006-10-17),

2. 6924365 - Optimized messenger RNA (2005-08-02),

3. 6858578 - Chimeric proteins for use in transport of a selected substance into cells (2005-02-22),

4. 6846676 - In Vivo production and delivery of erythropoietin or insulinotropin for gene therapy (2005-01-25),

5. 6692737 - In vivo protein production and delivery system for gene therapy (2004-02-17),

6. 6670178 - In Vivo production and delivery of insulinotropin for gene therapy (2003-12-30),

7. 6582391 - Hybrid matrix implants and explants (2003-06-24),

8. 6569681 - Methods of improving homologous recombination (2003-05-27),

9. 6566099 - Nucleic acid encoding a chimeric polypeptide (2003-05-20),

10. 6565844 - Protein production and protein delivery (2003-05-20),

11. 6537542 - Targeted introduction of DNA into primary or secondary cells and their use for gene therapy and protein production (2003-03-25),

12. 6531124 - In vivo production and delivery of insulinotropin for gene therapy (2003-03-11),

13. 6472181 - Hybrid matrix implants and explants (2002-10-29),

14. 6458574 - Treatment of a &agr;-galactosidase a deficiency (2002-10-01),

15. 6419920 - Hybrid matrix implants and explants (2002-07-16),

Transkaryotic Therapies, Inc. is a biotechnology company focused on developing and commercializing innovative treatments for genetic diseases. With a commitment to transforming the lives of patients, they employ advanced gene therapy and gene editing technologies to address unmet medical needs. Their research and development efforts aim to provide safe and effective therapies for a range of genetic disorders. Visit their website for more information about their groundbreaking work.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

40 Patents

#56 in Cambridge, MA

#484 in Massachusetts

#8,350 in US

#16,572 in the World

Cambridge, MA, United States of America

Transkaryotic Therapies, Inc.

Forward Citations = 1,233

15 inventors:

Douglas A Treco (31 out of 61 patents)

Richard F Selden (28 out of 30 patents)

Michael W Heartlein (26 out of 175 patents)

4. Carol M Kinoshita (5 out of 6 patents)

5. Marianne Borowski (5 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…